Get the Stockscreener App
0.2616
0.08%
0.0002
After Hours:
.27
0.0084
+3.21%
Ensysce Biosciences Inc stock is traded at $0.2616, with a volume of 223.79K.
It is up +0.08% in the last 24 hours and down -13.06% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.2614
Open:
$0.262
24h Volume:
223.79K
Relative Volume:
0.09
Market Cap:
$4.02M
Revenue:
$4.71M
Net Income/Loss:
$-11.79M
P/E Ratio:
-0.0781
EPS:
-3.3492
Net Cash Flow:
$-9.72M
1W Performance:
-3.00%
1M Performance:
-13.06%
6M Performance:
-69.11%
1Y Performance:
-88.32%
1-Day Range:
$0.255
$0.2778
1-Week Range:
$0.255
$0.2905
52-Week Range:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.2616 | 4.02M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
ENSC|Ensysce Biosciences Inc|Price:0.261|Chg%:-0.011 - TradingKey
TradingKey - TradingKey
Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ensysce Biosciences Inc (ENSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ensysce Biosciences Inc (ENSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026 - TradingView
COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10 - Stock Titan
Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026 - marketscreener.com
Ensysce receives $5.3M NIDA award for opioid overdose therapy By Investing.com - Investing.com Nigeria
Ensysce receives $5.3M NIDA award for opioid overdose therapy - Investing.com
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Weatherford Democrat
Federal funds back Ensysce opioid technology designed to limit overdose - Stock Titan
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - Yahoo Finance Singapore
Ensysce Biosciences (ENSC) Edges Higher: Key Support Holds as Volume Picks UpProfitability Factor - dars.gov.et
Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
12 Health Care Stocks Moving In Thursday's After-Market SessionSeer (NASDAQ:SEER), Universe Pharmaceut - Benzinga
Price to sales forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to revenue forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to earnings forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Price to book forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
Enterprise value to EBITDA forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC - TradingView
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Ensysce initiates final stage of opioid overdose protection study By Investing.com - Investing.com Nigeria
Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study - grafa.com
Ensysce initiates final stage of opioid overdose protection study - Investing.com
Ensysce starts final PF614-MPAR study stage for overdose-protection opioid - Stock Titan
Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC) - TradingView
ENSC Should I Buy - Intellectia AI
Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ENSYSCE BIOSCIENCES INC (ENSC) Stock Chart - ChartMill
Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ensysce Biosciences Slips 3.94% as Stock Tests Key Support at $0.23New Listing Stocks - newsline.com
ENSC Q1 2026 Earnings: Narrowing Losses Signal Progress Amid Market VolatilityEarnings Acceleration Picks - lwvtexas.org
Ensysce Biosciences Files for Sale of 1.3 Million Shares - Moomoo
Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale - Stock Titan
ENSC Q1 2026 Earnings: Narrower-Than-Expected Loss Despite No RevenueEarnings Whisper Number - The Legal Advocate
ENSC Q1 2026 Earnings: Narrower-than-expected loss boosts sharesMargin Guidance - newsline.com
Ensysce Biosciences (ENSC) Drops 3% as Stock Nears Support at $0.28MA Crossover - The Legal Advocate
Ensysce Biosciences (ENSC) Declines Further, Tests Key Support Near $0.29Diamond Pattern - Newser
ENSCEnsysce Biosciences Inc Stock Price and Quote - Finviz
Ensysce Faces New Nasdaq Issue as Deadline Nears - Bez Kabli
ENSC Q1 2026 Earnings: Narrower-than-expected Net Loss as EPS Beats EstimatesSegment Revenue Breakdown - The Legal Advocate
Ensysce Biosciences, Inc. Files Form 8-K: Company Details, Nasdaq Listing, and Compliance Update - Minichart
Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule - Investing.com
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):